Risk factors
Azitra (AZTR) risk factors
Item 1A of every Azitra, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors44 risks5 new2 dropped5 reworded
Cash and working capital fell, despite approximately $6 million from an equity line and additional offerings.
Filed Feb 27, 2026 - FY2024 10-K risk factors41 risks
Azitra is an early-stage biopharmaceutical company with an accumulated deficit of $57.6 million and net losses of $9.0 million in 2024. Operations depend entirely on the clinical success and regulatory approval of product candidates ATR-12 and ATR-04. The company requires additional financing and faces severe stock price volatility and potential delisting from the NYSE American.
Filed Feb 24, 2025